Ongoing trials in squamous cell cancer of the esophagus evaluate combination of tyrosine kinase inhibitors with PD-1/PD-L1 inhibitors (e.g., lenvatinib and pembrolizumab in LEAP 014 trial). This evidence concerns the gene CD274 and squamous cell carcinoma.